Clinical Trial Update: Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether adding dalteparin to gemcitabine improves outcomes in locally advanced or metastatic pancreatic cancer; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Venous Thromboembolism

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Hull University Teaching Hospitals NHS Trust | Conditions: Pancreatic Cancer, Thromboembolism | Phase 2 | Status: COMPLETED